CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer

Autor: Chiorean, E. G., Von Hoff, D. D., Reni, M., Arena, F. P., Infante, J. R., Bathini, V. G., Wood, T. E., Mainwaring, P. N., Muldoon, R. T., Clingan, P., Kunzmann, V., Ramanathan, R. K., Tabernero, Josep, Goldstein, D., McGovern, D., Lu, B., Ko, A., Universitat Autònoma de Barcelona

Publikováno v: Annals of Oncology
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona

Any CA19-9 decline at week 8 and radiologic response by week 8 each predicted longer OS in both treatment arms. In the nab-P + Gem arm, the higher proportion of patients with week 8 CA19-9 decrease [82% (206/252); median OS 13.2 months] than a RECIST

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37b543d690a6f45b63e2d66fead497c2
https://opus.bibliothek.uni-wuerzburg.de/frontdoor/index/index/docId/18965

CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.

Autor: Chiorean EG; Department of Medicine/Oncology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle gchiorea@uw.edu., Von Hoff DD; HonorHealth and The Translational Genomics Research Institute (TGen), Scottsdale, USA., Reni M; Department of Radiation Oncology, San Raffaele Scientific Institute, Milan, Italy., Arena FP; Department of Oncology, NYU Langone Arena Oncology, Lake Success., Infante JR; Sarah Cannon Research Institute, Tennessee Oncology, PLLC, Nashville., Bathini VG; Cancer Center of Excellence, University of Massachusetts Medical School, Worcester., Wood TE; UAB Comprehensive Cancer Center, Birmingham, USA., Mainwaring PN; Mater Private Centre for Haematology & Oncology, South Brisbane, Australia., Muldoon RT; Department of Oncology, Genesis Cancer Center, Hot Springs, USA., Clingan PR; Southern Medical Day Care Centre, Wollongong, Australia., Kunzmann V; Medizinische Klinik und Poliklinik II, University of Wuerzburg, Wuerzburg, Germany., Ramanathan RK; HonorHealth and The Translational Genomics Research Institute (TGen), Scottsdale, USA., Tabernero J; Medical of Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain., Goldstein D; Department of Oncology, Prince of Wales Hospital, Sydney, Australia., McGovern D; Celgene Corporation, Summit, USA., Lu B; Celgene Corporation, Summit, USA., Ko A; Celgene Corporation, Summit, USA.

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2016 Apr; Vol. 27 (4), pp. 654-60. Date of Electronic Publication: 2016 Jan 22.

5-Methyltetrahydrofolate is reabsorbed and metabolized in isolated perfused rat kidney.

Autor: Muldoon RT; Department of Pharmacology, Louisiana State University Medical Center, Shreveport 71130-3932., Eisenga BH, Morshed KM, McMartin KE

Publikováno v: The Journal of nutrition [J Nutr] 1992 Dec; Vol. 122 (12), pp. 2415-23.